Cargando…
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
BACKGROUND: Effective therapeutics to treat COVID-19 are urgently needed. Remdesivir is a nucleotide prodrug with in vitro and in vivo efficacy against coronaviruses. Here, we tested the efficacy of remdesivir treatment in a rhesus macaque model of SARS-CoV-2 infection. METHODS: To evaluate the effe...
Autores principales: | Williamson, Brandi N., Feldmann, Friederike, Schwarz, Benjamin, Meade-White, Kimberly, Porter, Danielle P., Schulz, Jonathan, van Doremalen, Neeltje, Leighton, Ian, Kwe Yinda, Claude, Pérez-Pérez, Lizzette, Okumura, Atsushi, Lovaglio, Jamie, Hanley, Patrick W., Saturday, Greg, Bosio, Catharine M., Anzick, Sarah, Barbian, Kent, Cihlar, Tomas, Martens, Craig, Scott, Dana P., Munster, Vincent J., de Wit, Emmie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239049/ https://www.ncbi.nlm.nih.gov/pubmed/32511319 http://dx.doi.org/10.1101/2020.04.15.043166 |
Ejemplares similares
-
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
por: Williamson, Brandi N., et al.
Publicado: (2020) -
Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques
por: Munster, Vincent J., et al.
Publicado: (2021) -
Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2
por: Williamson, Brandi N., et al.
Publicado: (2022) -
SARS-CoV-2 Omicron BA.1 and BA.2 are attenuated in rhesus macaques as compared to Delta
por: van Doremalen, Neeltje, et al.
Publicado: (2022) -
SARS-CoV-2 Omicron BA.1 and BA.2 are attenuated in rhesus macaques as compared to Delta
por: van Doremalen, Neeltje, et al.
Publicado: (2022)